Over 100 organoid models available

OcellO offers extracellular matrix-embedded organoid cultures for testing of small molecules and antibodies for oncology and immuno-oncology. Precise detection of therapeutic responses such as activity, toxicity, synergy as well as mode of action and interactions with added immune cells are tested in 3D culture and quantified using OcellO’s Ominer™ 3D image analysis software.

Well-characterized patient derived colon organoids from normal and tumor material

#C39

OcellO #C39 natural organoid

#C55

OcellO C55N Natural Organoid

#C57

OcellO C57N Natural Organoid

#C82

OcellO C82N Natural Organoid

#C92

OcellO C92N Natural Organoid

#C110

OcellO C110N Natural Organoid

Normal

OcellO C39T Tumor Organoid
OcellO C55T Tumor Organoid
OcellO C57T Tumor Organoid
OcellO C82T Tumor Organoid
OcellO C110T Tumor Organoid

Tumor

#C39#C55#C57#C82#C92#C110
APC
KRAS
PIK3CA
TP53
RNF43
FAM1B23
SOX9

The variation in mutations detected in colorectal cancer organoids derived from different patients results in diverse growth morphologies in response to the culture environment. Image-based analysis of organoids gives more insight into the effects of  compounds on the complex tumor biology, revealing effects and activities that cannot be revealed by conventional measurements of cell viability.

OcellO Projections of Actin+Hoechst P001H016 P18T
OcellO Projections of Actin+Hoechst P003 F013 P17T 3ch
OcellO Projections of Actin+Hoechst P003 H013 P14T 3ch

Rich, quantitative data describing drug responses

Low dose of 5-FU

OcellO Tumor low dose Organoid 5FU

High dose of 5-FU

OcellO Organoid Tumor high dose 5FU

Low dose of 5-FU

OcellO Organoid Normal organoid low dose 5FU

High dose of 5-FU

Tumor

Normal

OcellO’s advanced 3D image analysis measures tumour killing and non-lethal toxicities in both tumor and normal organoids derived from the same patient. This can help to predict potential off-target effects in subsequent in vivo studies. Here, 5-FU induces killing of tumor organoids, and thinning of the epithelial cell layer of normal colorectal organoids.

OcellO’s high content 3D screening platform enables basic measurement of number, shape & size of organoids, individual cells and nuclei. Additional intricate analysis of network formation, protrusions, lumen formation and planar polarity measurements are performed in order to obtain unique characterization of treatment effects on organoids with specific mutations and diverse genetic backgrounds.

  • > 80 sequenced tumour and normal intestinal organoids
  • Customizable high throughput screening platform (384-well plate format)
  • Measurement of > 500 features such as number, shape & size of nuclei, organoid & lumen formation or infiltration of immune cells
  • Quantitative analysis of growth, morphology, proliferation, cell cycle arrest, cell death, apoptosis and toxicity
  • Functional testing of antibodies, ADC’s, immune cell interactions and small molecules.

CRC organoid
screening
platform

Assay Principle

OcellO licenses tumor and normal colon organoids derived from biopsies from more than 100 patients by Hubrecht Organoid Technology (HUB). These genetically characterized organoids are expanded from their stem-cell compartment and cultured in 3D by OcellO and seeded in a 384-wells plate format for high throughput screening.

Assays can be customized to fit project needs – the organoid screening platform is suitable for testing libraries or dose ranges of immuno-oncology therapies, small molecules, (bispecific) antibodies, ADCs, compound combinations, inflammatory agents and toxic agents.

After a typical exposure time of 7 days the hundreds of organoids per well are fixed and stained to capture the cellular and tissue organisation of each individual organoid by automated z-stack imaging, followed by 3D image analysis in OcellO’s Ominer™ platform.

The >500 different morphological parameters that are measured are subsequently interrogated to obtain a drug response profile and determine the mode of action, growth (inhibiting) effect, promotion of cell death, alterations in polarity and reversal of mutation-driven signatures.

A unique image-based screening platform that provides detailed insight into the effect of therapies on diverse colon tumors.

Contact us

Ask your questions or request an introductory call

Find us here

OcellO B.V.
J.H. Oortweg 21
2333 CH Leiden
The Netherlands

Email [email protected]
Telephone +31 (0)71 3322 875 

Chamber of Commerce
(KvK) number: 53055926